Investors and analysts have given it some thought and mostly think it's a sensible acquisition. Source: BioSpace

These stocks have been given a Strong Buy or Buy rating by 80% or more brokers. Source: BioSpace

Fresh off its $7B acquisition, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey. Source: BioSpace

This Latest move is a wide-ranging effort to boost competitiveness. Source: BioSpace

The 2016 U.S. presidential election was marked by aggressive and often shrill attacks on the biopharma industry over drug pricing. Source: BioSpace

With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference. Source: BioSpace

resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace

On Jan. 8, Alder BioPharma announced that its eptinezumab met its primary endpoint in its Phase III PROMISE 2 clinical trial for preventing migraine. Source: BioSpace

Strongbridge will fund 70% of the costs of a worldwide pediatric development program to be run by Aeterna Zentaris with customary oversight from a joint steering committee. Source: BioSpace

There are many unusual things about Shepherd Therapeutics, but one of them is its origin. Source: BioSpace